Ongoing Securities Investigation into ADMA Biologics
Leading securities law firm Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) regarding possible violations of federal securities laws. This investigation comes in light of recent events that have raised concerns among investors and generated interest in legal recourse.
What Led to the Investigation?
ADMA Biologics is known for producing and marketing specialty biologics aimed at treating immunodeficient patients at risk of infections. The firm took a hit recently when they announced the sudden resignation of their independent outside auditor, CohnReznick LLP, on October 9, 2024. This unexpected change baffled many and consequently triggered a significant drop in stock price.
Impact on Investors
Following the auditor's resignation, ADMA Biologics experienced a shocking drop in stock value, with shares plummeting over 20% during trading, as reported on October 10, 2024. Such a decline understandably generated anxiety among shareholders regarding the firm’s financial health and governance, raising pertinent questions about potential irregularities.
Understanding the Concerns
With the loss in stock value, investors may be left wondering about the future of ADMA Biologics. The abrupt resignation of a key auditor can cast doubt on a company's operations, leading shareholders to reassess their investments. As a result, those who invested in ADMA find themselves at a crossroads and need clarity on their options moving forward.
Your Legal Options
If you happen to be one of the investors affected by this unsettling turn of events, it's essential to know that you have options. Legal representatives from Bleichmar Fonti & Auld LLP encourage individuals to consider their rights regarding potential securities fraud. Since you may have a case for recovery of losses, it's wise to act quickly and explore your legal alternatives.
How to Take Action
Interested parties are invited to submit their information for review. The law firm operates on a contingency fee basis, meaning there is no upfront cost to you. Investors need not worry about court costs or legal expenses, as the firm seeks court approval for any incurred fees related to the legal proceedings.
About Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is a distinguished international law firm recognized for its expertise in securities class actions and shareholder litigation. Renowned as one of the top plaintiff law firms, the company has successfully recovered significant amounts for investors in the past, positioning itself as an advocate for shareholders navigating complex legal landscapes.
Highlighted Achievements
Among the notable achievements of BFA is the recovery of over $900 million from Tesla, Inc.'s Board of Directors (pending court approval) and $420 million from Teva Pharmaceutical Industries Ltd. These accomplishments underscore the firm’s commitment to standing up for investors' rights in the face of corporate misconduct.
Frequently Asked Questions
What prompted the investigation into ADMA Biologics?
The investigation started due to the sudden resignation of their independent auditor, raising questions about potential violations of securities laws.
What happened to ADMA Biologics' stock price?
Following the auditor's resignation announcement, ADMA Biologics saw a decline in stock price exceeding 20% within a day of trading.
What should investors do if they incurred losses?
Investors can explore legal options available to them and are encouraged to submit their information for review without any upfront costs.
How can Bleichmar Fonti & Auld LLP help investors?
Bleichmar Fonti & Auld LLP can provide legal representation to affected investors, advocating for recovery of their losses in potential shareholder litigation.
What makes Bleichmar Fonti & Auld LLP a notable law firm?
The firm is recognized among the top plaintiff law firms and has successfully recovered substantial amounts for investors in prior cases.
